Some ingredients leave key questions open
The Food and Drug Administration (FDA) is the US drug regulator.
FDA warns that certain peptide ingredients can clump or contain unwanted material, which may cause the body to react as if an invader is present.
For BPC-157, FDA said it lacked enough information to know whether the proposed uses would harm people, in information checked September 26, 2026.
Preparation can change what is in the product
To compound a medicine is to make it up for a patient’s needs.
FDA says poor preparation can leave a medicine with unwanted material. The active ingredient may end up above or below its intended amount.
In letters to peptide sellers, FDA explained that injected products can get past defenses that normally block germs and toxins.
Use the product’s own storage directions
Peptide medicines do not all need the same storage. Ask for the directions for that product.
Ask the dispensing pharmacist to explain the label, storage and what to do if the delivery seems wrong.
If pregnancy or breastfeeding is relevant, ask for advice about the exact proposed product.
For a compounded medicine, there is no matching FDA-reviewed advice about use during pregnancy or while breastfeeding.
Treat severe allergy as an emergency
MedlinePlus, a US National Library of Medicine information service, describes severe allergy as an emergency.
MedlinePlus lists face or tongue swelling, trouble breathing or swallowing, and passing out among the symptoms.
MedlinePlus calls for immediate emergency-room care or an emergency call to 911 when symptoms are severe.
A medicine problem can be reported
MedWatch accepts reports from patients. It is FDA’s system for reporting problems with medical products.
A report alone cannot prove what caused the problem or how often it occurs.
Open the FDA reporting form